# Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields

Journal Article

**Author(s):**
Da Costa, Fernando P.; de Oliveira, A.C.; Meirelles, Rodrigo; Machado, Marcos C.; Zanesco, Tamires; Surjan, Rodrigo; Chammas, Maria Cristina; de Souza Rocha, Manoel; Morgan, Kathryn; Cantor, Alan; Zimmermann, J. Paul; Brezovich, Ivan; Kuster, Niels; Barbault, Alexandre; Pasche, Boris

# Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields

**FP Costa**[*,1], **AC de Oliveira**[1], **R Meirelles**[1], **MCC Machado**[1], **T Zanesco**[1], **R Surjan**[1], **MC Chammas**[2], **M de Souza Rocha**[2], **D Morgan**[3], **A Cantor**[4], **J Zimmerman**[5], **I Brezovich**[6], **N Kuster**[7], **A Barbault**[8] and **B Pasche**[*,5]

[1]Department of Transplantation and Liver Surgery, Hospital das Clínicas da Faculdade de Medicina, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, 255, São Paulo 05403-000, Brazil; [2]Department of Radiology, Hospital das Clínicas, University of São Paulo, São Paulo 05403-000, Brazil; [3]Department of Radiology, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA; [4]Biostatistics and Bioinformatics Shared Facility, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA; [5]Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham and UAB Comprehensive Cancer Center, 1802 6th Ave South, NP 2566, Birmingham, AL 35294-3300, USA; [6]Department of Radiation Oncology, The University of Alabama at Birmingham and UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA; [7]IT'IS Foundation, Swiss Federal Institute of Technology, Zurich, Switzerland; [8]Rue de Verdun 20, Colmar 68000, France

BACKGROUND: Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies.
METHODS: A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival ⩾6 months. Secondary efficacy end points were progression-free survival and overall survival.
RESULTS: Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1–5.3) and median overall survival was 6.7 months (95% CI 3.0–10.2). There were three partial and one near complete responses.
CONCLUSION: Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of antitumour effects in patients with advanced HCC.

Treatment of inoperable or metastatic solid tumours is a major challenge in oncology, which is limited by the small number of therapeutic agents that are both well tolerated and capable of long-term control of tumour growth. Hepatocellular carcinoma (HCC) is the second most common cause of cancer death in men and the sixth in women worldwide (Jemal *et al*, 2011). Hepatocellular carcinoma is the most common tumour in certain parts of the world, particularly in East Asia, Africa, and certain countries of South America. This tumour is less frequent in Europe and in the United States, but has become the fastest rising cancer in the United States (Jemal *et al*, 2011). In the United States alone, it is estimated that 24 120 new cases were diagnosed and there were 17 430 deaths from HCC in 2010 (Jemal *et al*, 2010), a 27% increase in the number of new cases since 2004 (Jemal *et al*, 2004). The

prognosis of patients suffering from advanced HCC is poor with an average survival of fewer than 6 months (Kassianides and Kew, 1987; Jemal *et al*, 2011).

Therapies for HCC are limited. Resections of the primary tumour or liver transplantation are the preferred therapeutic approaches in patients who are surgical candidates (Bruix and Sherman, 2005). Although these interventions result in long-term survival for some patients, only a minority benefit from them because of limitations due to tumour size, patient's overall condition, and presence of hepatic cirrhosis (Cance *et al*, 2000). Only a small number of randomised trials show a survival benefit in the treatment of HCC. Chemoembolisation has been shown to confer a survival benefit in selected patients with unresectable HCC (Llovet *et al*, 2002). Data from two phase III randomised placebo-controlled studies demonstrate improved survival in patients with advanced HCC receiving the multikinase inhibitor sorafenib (Llovet *et al*, 2008b; Cheng *et al*, 2009). Additional therapies for this disease are sorely needed, especially for the large number of patients with advanced disease who cannot tolerate

BJC
OPEN 🔓

Treatment of HCC with AM EMF
FP Costa et al

npg

641

**Figure 1** Delivery of HCC-specific modulation frequencies. (**A**) The generator of AM EMFs is a battery-driven RF EMF generator connected to a spoon-shaped mouthpiece. (**B**) Schematic description of AM EMFs. The carrier frequency (27.12 MHz) is sinusoidally modulated at specific frequencies. (**C**) Patient receiving treatment with RF AM EMF. (**D**) HCC treatment programme consisting of sequential emission of 194 modulation frequencies for 60 min.

chemotherapy or intrahepatic interventions because of impaired liver function (Thomas and Zhu, 2005).

The intrabuccal administration of low and safe levels of electromagnetic fields, which are amplitude-modulated at disease-specific frequencies (RF AM EMF) (Figure 1), was originally developed for the treatment of insomnia (Pasche et al, 1990). The highest levels of EMFs encountered during treatment are found at the interface between the tongue and the mouth probe and are compliant with international safety limits (ICNIRP, 1998; Pasche and Barbault, 2003). Tumour-specific modulation frequencies have been identified for several common forms of cancer and one report suggests that this novel therapeutic approach is well tolerated and may be effective in patients with a diagnosis of cancer (Barbault et al, 2009). However, the safety and potential efficacy of this treatment approach in the treatment of advanced HCC are unknown. We designed this single-group, open-label, phase I/II study to assess the feasibility of this treatment in patients with advanced HCC and limited therapeutic options.

## PATIENTS AND METHODS

### Patients

The study was aimed at offering treatment to patients with Child–Pugh A or B advanced HCC and limited therapeutic options. Patients were classified as having advanced disease if they were not

eligible for surgical resection or had disease progression after surgical or locoregional therapies or had disease progression after chemotherapy or sorafenib therapy. Patients with measurable, inoperable HCC were eligible for enrolment. Previous local or systemic treatments were allowed as long as they were discontinued at least 4 weeks before enrolment. Inclusion criteria included Eastern Cooperative Oncology Group performance status of 0, 1, or 2 and biopsy-confirmed HCC. Also allowed were patients with no pathological confirmation of HCC with a level of α-fetoprotein higher than 400 ng ml$^{-1}$ and characteristic imaging findings as assessed by multislice computer tomography (CT) scan or intravenous contrast ultrasound (US). As per the University of São Paulo Department of Transplantation and Liver Surgery guidelines, liver biopsies are avoided in patients eligible for transplant or with severely impaired liver function. Exclusion criteria included confirmed or suspected brain metastasis, Child–Pugh C, previous liver transplant, and pregnancy.

### Study design

This was an investigator-initiated, single centre, uncontrolled phase I/II trial in patients with advanced HCC. The trial was approved by the local human investigation committee and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient. The protocol was registered: clinicaltrial.gov identifier no. NCT00534664.

Consort diagram

Assessed for eligibility (*n* = 267)

Patients not eligible according to investigator (*n* = 224)
- Other standard treatment options available
- Patient too sick to undergo experimental therapy
- Patient not willing to participate

Screened patients (*n* = 43)

Allocated to intervention (*n* = 43)

Received allocated intervention (*n* = 41)

Did not receive allocated intervention – screen failures (*n* = 2)
- Biopsy-confirmed metastatic breast cancer (*n* = 1)
- Impaired liver function – Child-Pugh C11 (*n* = 1)

First cohort (*n* = 23)
- Progression-free survival ⩾ 6 months (*n* = 6)
Second cohort (*n* = 18)

Lost to follow-up (*n* = 2)
- Lost contact, date of death is unknown (*n* = 1)
- Missed return visits, date of death is known (*n* = 1)

Discontinued intervention - withdrew consent (*n* = 4)
- To receive chemotherapy (*n* = 1)
- To undergo liver transplantation (*n* = 1)
- To enroll in another experimental protocol (*n* = 1)
- Poor treatment compliance (*n* = 1)

Allocated for survival analysis (*n* = 41)

Excluded from survival analysis
- Lost to follow-up, date of death unknown (*n* = 1)

Eligible for survival analysis (*n* = 40)

Discontinuation not due to tumour progression (*n* = 14)
- GI bleed (*n* = 4)
- Sepsis (*n* = 3)
- Liver failure (*n* = 3)
- Myocardial infarction (*n* = 1)
- COPD complications (*n* = 1)
- Chemo/chemoembolization complications (*n* = 2)

Discontinuation due to tumour progression (*n* = 24)
Lost to follow-up, date of death is known (*n* = 1)
Alive as of June 9, 2011 (*n* = 1)

Allocated for tumour response analysis (*n* = 41)

Excluded from tumour response analysis
- Lost to follow-up (*n* = 2)
- Withdrew consent before tumour evaluation (*n* = 3)
- Death prior to tumour re-evaluation (*n* = 8)

Eligible for tumour response analysis (*n* = 28)

Imaging studies
- CT scan (± contrast-enhanced US) (*n* = 19)
- Contrast-enhanced US only (*n* = 9)

Tumour progression before study entry (*n* = 22)

*Enrolment | Allocation | Follow-up | Efficacy analysis*

**Figure 2** CONSORT diagram.

## Administration of AM EMFs

The generator of AM EMFs consists of a battery-driven radio-frequency (RF) EMF generator connected to a 1.5 m long 50 Ω coaxial cable, to the other end of which a stainless-steel spoon-shaped mouthpiece is connected via an impedance transformer (Figure 1A). The RF source of the device corresponds to a class C amplifier operating at 27.12 MHz. The carrier frequency is AM (Figure 1B) with a modulation depth of $85 \pm 5\%$, whereas the modulation frequency is generated by a digital direct synthesiser with a resolution of $10^{-7}$. The treatment sequence is controlled by a microcontroller (Atmel AT89S8252, Fribourg, Switzerland), that is, duration of session, sequence of modulation frequencies and duration of each sequence can be programmed via PC over a RS232 interface. The RF output is adjusted to 100 mW into a 50 Ω load, which results in an emitting power identical to that of the device used for the treatment of insomnia (Pasche *et al*, 1990; Reite *et al*, 1994; Pasche *et al*, 1996). The United States Food and Drug Administration has determined that such a device is not a significant risk device and it has been used in several studies conducted in the United States (Reite *et al*, 1994; Pasche *et al*, 1996; Kelly *et al*, 1997). A long-term follow-up survey of 807 patients who have received this therapy in the United States, Europe and

Asia showed that the rate of adverse reactions was low and was not associated with increases in the incidence of malignancy or coronary heart disease (Amato and Pasche, 1993). The maximum specific absorption rate (SAR) of the applied RF averaged over any 10 g of tissue has been estimated to be less than $2 \, \mathrm{W \, kg^{-1}}$, and the maximum temperature increase is significantly lower than 1 °C anywhere in the body owing to RF absorption. The induced RF field values within the primary and metastatic tumours are significantly lower. In contrast, the RF fields induced during RF ablation of tumours cause hyperthermia and result in SAR in the range of $2.4 \times 10^5 \, \mathrm{W \, kg^{-1}}$ (Chang, 2003), that is, more than 100 000 times higher than those delivered by the device used in this study.

We have previously reported the discovery of HCC-specific modulation frequencies in 46 patients with HCC using a patient-based biofeedback approach and shown the feasibility of using AM EMFs for the treatment of patients with cancer (Barbault *et al*, 2009). The treatment programme used in this study consisted of three-daily outpatient treatments of 1 h duration, which contained HCC-specific modulation frequencies ranging between 100 Hz and 21 kHz administered sequentially, each for 3 s (Figure 1C and Supplementary Table S1).

The treatment method consists of the administration of AM EMFs by means of an electrically conducting mouthpiece, which is

in direct contact with the oral mucosa (Figure 1D). The patients were instructed on the use of the device and received the first treatment at the medical centre's outpatient clinic. A device was provided to each patient for the duration of the study. The patients were advised to self-administer treatment three times a day. Treatment was administered until tumour progression was objectively documented. At that time, treatment was discontinued. Treatment compliance was assessed at every return visit by recording the number of treatments delivered in the preceding 2 months.

## Efficacy end points and disease assessment

The primary end point of this trial was the proportion of patients progression-free at 6 months. Secondary end points were progression-free survival (PFS) (first day of treatment until progression of disease or death) and overall survival (OS) (first day of receiving treatment to death). Objective response was assessed using the Response Evaluation Criteria in Solid Tumours group classification for patients with disease assessed by either helical multiphasic CT (Therasse *et al*, 2000). Whenever contrast-enhanced US radiological assessment was used, it was performed and reviewed by the same radiologist specialised in HCC (MCC) as this imaging modality is investigator dependent. Tumour measurements were performed at baseline and every 8 weeks. Only patients with at least one repeat tumour measurement during therapy were considered for response analysis. Throughout the study, lesions measured at baseline were evaluated using the same technique (CT or contrast-enhanced US). Overall tumour response was scored as a complete response (CR), partial response (PR), or stable disease (SD) if the response was confirmed at least 4 weeks later. Alpha-fetoprotein (AFP) levels were measured every 8 weeks in all patients throughout the study, but changes in AFP were not an end point for assessment of response. Pain was assessed according to the NCI-CTCAE v.3.0 (http://ctep.cancer.gov/proto-colDevelopment/electronic_applications/docs/ctcaev3.pdf).

## Statistical analyses and efficacy assessment

All eligible patients who began treatment were considered assessable for the primary and secondary end points. A Simon two-stage phase II minimax design was used (Simon, 1989) to evaluate the rate of progression-free survival at 6 months. The interim analysis was performed once enrolment into the first stage was completed. In the first stage, 23 patients were observed. If two or fewer patients had progression-free survival $\geq 6$ months, the trial would be terminated early for lack of efficacy. If the progression-free survival of 3 or more of the first 23 patients was equal or greater than 6 months, then an additional 18 patients would be enrolled to a maximum of 41 patients. If eight or more of the 41 had PFS of at least 6 months, we would conclude that the treatment was efficacious. This design had a Type I error rate of 5% and a Type II error rate of 10% for the null hypothesis of a 6-month PFS rate of 10% vs the alternative of 27.5%. Kaplan–Meier estimates of survival, PFS, and duration of response were calculated with standard errors based on Greenwood's formula. These calculations were performed using the Proc Lifetest in SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

## RESULTS

## Patient recruitment and follow-up

From October 2005 to July 2007, 267 patients were assessed for eligibility (Figure 2). In all, 43 patients with advanced HCC and Child–Pugh A or B were enrolled in this study. The date of last patient follow-up is 9 June 2011. Of these, 20 patients (46.5%) had histological confirmation of HCC; 23 patients (53.5%) were

**Table 1** Treatments received by patients with advanced HCC before enrolment ($n = 41$)

| | |
|---|---|
| No previous treatment | 7 |
| Chemoembolisation | 25 |
| ^{131}I-Lipiodol | 1 |
| Octreotide | 1 |
| Percutaneous alcohol injection therapy | 1 |
| Surgery | 9 |
| Systemic chemotherapy or sorafenib | 5 |

Abbreviation: HCC = hepatocellular carcinoma. Two patients had surgery and chemoembolisation, two patients had surgery and systemic chemotherapy, one patient had surgery and chemoembolisation and systemic chemotherapy, one patient had surgery and percutaneous alcohol injection, one patient had surgery and sorafenib, one patient had chemoembolisation and systemic chemotherapy and one patient had surgery and octreotide.

**Table 2** Patients' baseline characteristics

| | No. | % |
|---|---|---|
| *Age (years)* | | |
| Median age | 64 | |
| Range | 18–85 | |
| $\geq 65$ | 19 | 46.3 |
| <65 | 22 | 53.6 |
| | | |
| *Sex* | | |
| Female | 6 | 14.6 |
| Male | 35 | 85.4 |
| | | |
| *ECOG performance status* | | |
| 0 | 5 | 12.2 |
| 1 | 28 | 68.3 |
| 2 | 8 | 19.5 |
| | | |
| *Child–Pugh status* | | |
| A5 | 15 | 36.6 |
| A6 | 2 | 4.9 |
| B7 | 6 | 14.6 |
| B8 | 5 | 12.2 |
| B9 | 11 | 26.8 |
| No cirrhosis | 2 | 4.9 |
| | | |
| *BCLC status* | | |
| B | 6 | 14.6 |
| C | 35 | 85.4 |
| | | |
| *AFP > ULN* | | |
| Yes | 28 | 68.3 |
| No | 13 | 16.7 |
| | | |
| *Aetiology* | | |
| ETOH | 2 | 4.9 |
| Hepatitis B | 6 | 14.6 |
| Hepatitis B+C | 1 | 2.4 |
| Hepatitis C | 22 | 53.7 |
| ETOH+hepatitis C | 1 | 2.4 |
| NOS | 9 | 22.0 |
| | | |
| Portal thrombosis | 10 | 24.3 |
| *Extrahepatic disease* | | |
| Yes | 16 | 39.0 |
| Location | | |
| Lung | 6 | 14.6 |
| Bone | 3 | 7.3 |
| Lymph nodes | 4 | 9.8 |
| Peritoneal carcinomatosis | 1 | 2.4 |
| Adrenal gland | 1 | 2.4 |

Abbreviations: AFP = α-fetoprotein; BCLC = Barcelona Clinic Liver Cancer; ECOG = Eastern Cooperative Oncology Group; ETOH, ethyl alcohol; ULN, upper limit of normal.

**Figure 3** Progression-free and overall survival. (**A**) Median progression-free survival was 4.4 months (95% CI 2.1–5.3). (**B**) Median overall survival was 6.7 months (95% CI 3.0–10.2). (**C**) Long-term partial response in a patient with biopsy-proven hepatocellular carcinoma. A 76-year-old woman with hepatitis C and Child–Pugh A5, BCLC C, biopsy-proven hepatocellular carcinoma with bilateral pulmonary metastases, who had evidence of disease progression (+36% by Response Evaluation Criteria in Solid Tumours (RECIST) criteria) between 3 May 2006 (first column) and 26 July 2006 (second column) while enrolled in the SHARP study (Llovet *et al*, 2008b). Treatment with AM EMFs was initiated on 9 August 2006. Subsequent restaging multiphasic contrast-enhanced computed tomographies (CTs) with images from corresponding levels (across rows) are demonstrated in the third and fourth columns over the course of 57 months. Note that the hypervascularity of the focal hepatic lesions (arrows in first two rows) became relatively hypoenhancing on arterial phase (20 August 2008). The patient developed main portal vein thrombosis with cavernous transformation as a complication of her cirrhosis. However, the intrahepatic lesion size is stable regardless of enhancement pattern. Note also that the left lung base lesion resolved (4th row), and the right lung base lesion remained stable (3rd row) over the duration of treatment. (**D**) Alpha-fetoprotein response in a 67-year-old patient with Child–Pugh A5, BCLC C HCC and hepatitis C (hepatitis B negative).

diagnosed based on elevated levels of α-fetoprotein and characteristic imaging findings such as vascular invasion and characteristic differences in tumour blood flow. One patient was excluded because liver biopsy established the diagnosis of metastatic breast cancer. Another patient was excluded because of severely impaired liver function (Child–Pugh C11). These two patients who did not meet the inclusion criteria were registered as screening failures. Hence, a total of 41 patients were eligible to receive experimental therapy (Figure 2).

Two patients were lost to follow-up as they did not come back for their scheduled appointments. Repeated efforts were made to reach the patients and their families. The date of death of only one patient is known, and no information on response to treatment is available for either patient. Four patients withdrew consent while receiving therapy after 8.0, 9.3, 20.3, and 21.0 months, respectively (Figure 2). One patient elected to receive chemotherapy, one patient had poor treatment compliance as defined by administration of less than 50% of planned treatments at two consecutive return visits, one patient

elected to enrol in another experimental protocol, and one patient requested to be considered for liver transplantation as part of an extended indication, which does not fulfil the Milan criteria (Mazzaferro *et al*, 1996). This latter patient experienced disease progression and was ultimately not eligible for liver transplantation. Of the 35 patients who discontinued experimental therapy, four died of gastrointestinal bleeding, three of sepsis, three of hepatic failure, one of chronic obstructive pulmonary disease, two of chemotherapy- and chemoembolisation-related complications, and one of myocardial infarction (Figure 2). The remaining 24 patients discontinued because of disease progression assessed by imaging or significant clinical deterioration as assessed by the investigator (Figure 2). Estimated 60-day mortality was 27.8%; seven of 10 deaths were directly related to progression of disease. They were caused by liver failure in association with significant hepatic tumour involvement, without other cause of death, other than tumour involvement. Two deaths were secondary to gastrointestinal bleeding. One death was due to liver failure.

A total of 31 patients (75.6%) had radiological evidence of disease progression at the time of enrolment as defined by comparison of baseline imaging studies, with imaging studies obtained within the previous 6 months; 34 (82.9%) patients had received therapy before enrolment, five (14.6%) of them systemic chemotherapy or sorafenib (Table 1). Seven (17.1%) patients had not received therapy before enrolment for the following reasons: (1) severely impaired liver function in five cases; and (2) two patients refused to receive chemotherapy for metastatic disease. As shown in Table 2, the majority of patients had severely impaired liver function as demonstrated by the fact that 22 (53.7%) patients had Child–Pugh B disease and 35 (85.4%) BLCL stage C disease.

**Table 3** Independently reviewed best response (N = 41)

| Best response | No. | % |
|---|---|---|
| Partial response[a] | 4 | 9.8 |
| Stable disease[b] | 16 | 39.0 |
| Progressive disease | 8 | 19.5 |
| Not available for response assessment | 13 | 31.7 |

[a]Duration of the partial responses were +58.0, 46.9, 14.5 and 5.3 months (patient withdrew consent to undergo liver transplant). [b]To be classified as a stable disease, patients needed to have stable disease for ⩾12 weeks.

## Treatment efficacy

Six of the first 23 patients (26.1%) had progression-free survival ⩾6 months, which led us to continue enrolling patients up to the preplanned total of 41 patients (Figure 2). In total, 14 patients (34.1%) had SD for more than 6 months, which met our preplanned primary efficacy end point. Median progression-free survival was 4.4 months (95% CI 2.1–5.3) and median OS was 6.7 months (95% CI 3.0–10.2) (Figure 3A and B). One patient, previously enrolled in the SHARP study (Llovet *et al*, 2008b) and with evidence of disease progression at the time of enrolment, remains on therapy with a near complete response for 58 months (Figure 3C). Estimated survival at 12, 24 and 36 months is 27.9% (s.e. = 7.1%), 15.2% (s.e. = 5.7%), and 10.1% (s.e. = 4.8%), respectively. Subset analyses by Child-Pugh stage and accompanying figures are reported in Supplementary Information.

A total of 28 patients were evaluable for tumour response (Figure 2). Four (9.8%) patients had a partial response assessed with CT with or without contrast-enhanced ultrasound (Table 3). All partial responses were independently reviewed by two authors (MSR and DM). Three patients had biopsy-confirmed HCC and three had radiological evidence of disease progression at the time of enrolment (Table 4). Two patients had Child–Pugh A, one Child–Pugh B disease, and one had no cirrhosis. One of these

**Table 4** Characteristics of patients with either PR and/or long-term survival in excess of 24 months

| Age at enrolment and sex | Race | Cause/ cirrhosis (Child–Pugh) | Previous treatment/ resection | AFP↑/ pathology confirmation | Extra hepatic metastasis/ portal thrombosis | BCLC | Okuda | CLIP | MELD | Progression before study entry/ response | Treatment duration/ overall survival (months) | Cause of death | Treatment received after completion of experimental therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62 M | Caucasian | Hep C/yes (A5) | Yes/no | Yes/yes | No/no | B | I | 0 | 6 | Yes/N/A | 2.0/32.0 | Tumour progressed | Systemic chemotherapy |
| 67 F | Caucasian | Hep C/yes (B9) | Yes/no | Yes/yes | No/no | C | 2 | 2 | II | Yes/PR | 11.7/11.7 | GI bleed | None |
| 30 M | Black | NOS/no | Yes/es | No/yes | No/no | B | N/A | N/A | N/A | No/PR | 13.5/37.6 | Tumour progressed | Chemoembolisation and systemic chemotherapy |
| 61 M | Caucasian | Hep C/yes (A5) | Yes/no | No/no | No/no | C | I | I | 6 | Yes/SD | 26.8/26.8 | COPD | None |
| 56 M | Caucasian | Hep B/C/yes (A5) | No/no | Yes/no | No/no | B | I | 0 | 10 | Yes/SD | 4.9/50.3 | Tumour progressed | Chemoembolisation |
| 63 M | Caucasian | Hep C/yes (A5) | Yes/no | Yes/no | No/no | C | I | I | 4 | Yes/PR | 4.9/14.3 | Tumour progressed | None |
| 76 F | Caucasian | Hep C/yes (A5) | No/no | No/no | No/yes | C | I | I | 6 | Yes/SD | 44.6/44.6 | Tumour progressed | None |
| 76 F | Caucasian | Hep C/yes (A5) | No/yes | No/yes | Yes/yes | C | I | I | 6 | Yes/PR | +58.0/+58.0 | On therapy | Still receiving experimental treatment |

Abbreviations: AFP = α-fetoprotein; BCLC = Barcelona Clinic Liver Cancer; CLIP = Cancer Liver Italian Programme; GI = gastrointestinal; MELD = Model for end-stage liver disease; N/A = not applicable; PR = partial response; SD = stable disease.

**Table 5** Changes in AFP levels

| Patient age and gender | AFP 6 months (ng ml⁻¹) | Baseline AFP (ng ml⁻¹) | 8-week AFP (ng ml⁻¹) | AFP variation (%) | Treatment duration (months) | End treatment status | Virus status |
|---|---|---|---|---|---|---|---|
| 65 M | 4.31 | 9.76 | 5.95 | −39.0 | 3.0 | Progression-death | HepC |
| 67 F | 888.3 | 9022.0 | 238.0 | −97.3 | 11.7 | GI bleed-death | HepC |
| 64 M | 4.7 | 4.5 | 2.6 | −42.2 | 8.8 | AMI-death | HepB |
| 18 M | 6.7 | 35.7 | 16.4 | −55.7 | 7.8 | Revoked consent-death | NOS |

Abbreviations: AFP = α-fetoprotein; AFP 6 months = AFP measured within 6 months before enrolment; AMI = acute myocardial infarction; baseline AFP = AFP at treatment initiation; GI = gastrointestinal; HepB = hepatitis B virus; HepC = hepatitis C virus; NOS = not otherwise specified; 8-week AFP = AFP at 8 weeks during treatment.

*Translational Therapeutics*

patients without biopsy-proven disease subsequently withdrew consent after 4.9 months to undergo liver transplantation. The patient died of progression of disease 9.4 months later before undergoing liver transplantation. One patient with Child–Pugh B disease had a partial response lasting 11.7 months and died of gastrointestinal bleeding. One patient died of disease progression at 44.6 months. Overall, there were six long-term survivors with an OS greater than 24 months and four long-term survivors with an OS greater than 3 years. Importantly, five of the six (83%) long-term survivors had radiological evidence of disease progression at the time of study enrolment (Table 4). Two of three patients with the longest survival (44.6 and +58 months) had radiological evidence of disease progression at the time of enrolment, BLCL stage C disease, as well as portal vein thrombosis, three predictors of short survival (Llovet *et al*, 2003). Serial AFP measurements, which predict radiological response and survival in patients with HCC (Chan *et al*, 2009; Riaz *et al*, 2009), were available for 23 patients. AFP decreased by 20% or more in four (9.8%) patients following initiation of therapy (Table 5). Figure 3D shows the time course of a 37-fold decrease in AFP in a patient who had a long-lasting (11.7 months) partial response as assessed by CT.

In all, 11 patients reported pain before treatment initiation, 3 patients reported grade 3, 5 patients reported grade 2, and 3 patients grade 1. Five patients reported complete disappearance of pain and two patients reported decreased pain shortly after treatment initiation. Two patients reported no changes and two patients reported increased pain. There were no treatment-related grade 2, 3, or 4 toxicities. The only treatment-related adverse events were grade 1 mucositis (one patient) and grade 1 somnolence (one patient) over a total of 266.8 treatment months.

## DISCUSSION

Treatment with AM EMFs did not show any significant toxicity despite long-term treatment. The lack of toxicity experienced by the 41 patients presented in this report as well as the 28 patients from our previous report (Barbault *et al*, 2009) can be readily explained by the very low and safe levels of induced RF EMFs, which are more than 100 000 times lower than those delivered during RF ablation procedures (Chang, 2003). Hence, the putative mechanism of action of this novel therapeutic approach does not depend on temperature changes within the tumour.

These data are comparable to recent phase II studies evaluating the effectiveness of standard chemotherapy as well as novel targeted therapies in HCC (Abou-Alfa *et al*, 2006; Boige *et al*, 2007; Chuah *et al*, 2007; Cohn *et al*, 2008; Dollinger *et al*, 2008; Siegel *et al*, 2008). In a large phase II study assessing the effects of sorafenib in patients with HCC and Child–Pugh A and B who had not received previous systemic treatment, Abou-Alfa *et al* (2006) observed partial responses using the WHO criteria in 2.2% of patients. Investigator-assessed median time to progression was 4.2 months, and median OS was 9.2 months. Of note, all 137 patients from that study had evidence of disease progression after 14.8 months (Abou-Alfa *et al*, 2006), whereas, at the same time point, four (9.8%) of the patients enrolled in this study did not have evidence of disease progression. These findings suggest that RF AM EMF may increase the time to radiological progression in advanced HCC.

The majority of patients enrolled in this study had either failed standard treatment options or had severely impaired liver function that limited their ability to tolerate any form of systemic or intrahepatic therapy. Indeed, 16 patients (39.0%) had Child–Pugh B8 or B9 disease. Among these patients, the median progression-free survival was 4.4 months (95% CI 1.6–7.6 months), which is identical to that of the entire group. Five of these 16 patients (31.3%) received therapy for more than 7.5 months, which indicates that this therapy is well tolerated even in patients with severely impaired liver function.

Previous treatment with standard chemotherapy or sorafenib does not seem to impact the effectiveness of AM EMFs in the treatment of HCC. Indeed, three of the four patients who had a



**Figure 4**  A 70-year-old man with recurrent thyroid cancer metastatic to the lungs: stable disease at 57.5 months. Long-term stable disease in a 70-year-old man with recurrent biopsy-proven thyroid carcinoma metastatic to the lungs enrolled in the previously published feasibility study (Barbault *et al*, 2009). Treatment with AM EMFs was initiated on 20 August 2006. As of 9 June 2011, the patient is asymptomatic and still receiving treatment with no evidence of disease progression. Images through the target metastatic lesion in the right hilum demonstrate minimal size change over the 4 years, given differences in computed tomography acquisition techniques over that time interval.

BJC
OPEN

Treatment of HCC with AM EMF
FP Costa et al

npg

647

partial response while receiving AM EMFs had received previous systemic therapies (chemotherapy and sorafenib) and one had received intrahepatic therapy with ^{131}I-lipiodol.

Tumour shrinkage as assessed by radiological imaging as well as changes in AFP levels were documented in patients with advanced HCC receiving RF EMF modulated at HCC-specific frequencies administered by an intrabuccal probe. Antitumour activity in patients with advanced HCC was exemplified by partial responses observed in four patients (9.8%) and decreases in AFP levels greater than 20% in four patients. A total of 18 patients (43.9%) either had objective response or SD ≥ 6 months.

Importantly, this therapeutic approach has long-lasting therapeutic effects in several patients with metastatic cancer. Two of these patients, one with recurrent thyroid cancer metastatic to the lungs (Figure 4) enrolled in our feasibility study (Barbault et al, 2009) and the patient shown in Figure 3C, are still receiving treatment without any evidence of disease progression and without side effects almost 5 years after being enrolled in these studies. These findings suggest that, in some patients, this therapeutic approach may achieve permanent control of advanced cancer with virtually no toxicity.

Our phase I/II study has several limitations. First, only 19 of the 41 patients had biopsy-proven HCC, and the others were diagnosed by clinical criteria, an approach similar to that used in a recently reported phase II trial evaluating the clinical and biological effects of bevacizumab in unresectable HCC (Siegel et al, 2008). Importantly, analysis restricted to these 19 patients shows rates of progression-free survival at 6 months, median progression-free survival and OS that are similar to those without biopsy-proven HCC (Supplementary Figures 1C and D). Furthermore, three of the four partial responses were observed in patients with biopsy-proven HCC. Hence, these findings strongly suggest that treatment with AM EMFs yields similar results in patients with and without biopsy-confirmed HCC. Another potential limitation of our study consists in the use of contrast-enhanced ultrasound for the monitoring of some patients with HCC. It should be pointed out that recent studies indicate that the use of this imaging technique is comparable to that of CT scan with respect to the measurement of HCC tumours (Choi, 2007; Maruyama et al, 2008).

Antitumour response is considered the primary end point for phase II studies to proceed to further investigations. Studies applying Cox proportional hazards analysis indicate that this end point is consistently associated with survival in trials of locoregional therapies for HCC (Llovet et al, 2002) and a recent consensus article suggests that randomised studies are necessary to capture the true efficacy of novel therapies in HCC (Llovet et al, 2008a). In summary, the encouraging findings from this study warrant a randomised study to determine the impact of AM EMFs on OS and time to symptomatic progression.

## ACKNOWLEDGEMENTS

## Conflict of interest

AB and BP have filed a patent related to the use of electromagnetic fields for the diagnosis and treatment of cancer. AB and BP are founding members of TheraBionic LLC.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

## REFERENCES

Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De GJ, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. *J Clin Oncol* 24(26): 4293–4300

Amato D, Pasche B (1993) An evaluation of the safety of low energy emission therapy (published erratum appears in *Compr Ther* 1994;20(12):681. *Compr Ther* 19: 242–247

Barbault A, Costa F, Bottger B, Munden R, Bomholt F, Kuster N, Pasche B (2009) Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. *J Exp Clin Cancer Res* 28(1): 51

Boige V, Raoul JL, Pignon JP, Bouche O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M (2007) Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. *Br J Cancer* 97(7): 862–867

Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. *Hepatology* 42(5): 1208–1236

Cance WG, Stewart AK, Menck HR (2000) The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985–1996. *Cancer* 88(4): 912–920

Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. *J Clin Oncol* 27(3): 446–452

Chang I (2003) Finite element analysis of hepatic radiofrequency ablation probes using temperature-dependent electrical conductivity. *Biomed Eng Online* 2: 12

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 10(1): 25–34

Choi BI (2007) Doppler and harmonic ultrasound for hepatocellular carcinoma. *Hepatol Res* 37(Suppl 2): S172–S177

Chuah B, Lim R, Boyer M, Ong AB, Wong SW, Kong HL, Millward M, Clarke S, Goh BC (2007) Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. *Acta Oncol* 46(2): 234–238

Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L (2008) A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. *Invest New Drugs* 26(4): 381–386

Dollinger MM, Behrens CM, Lesske J, Behl S, Behrmann C, Fleig WE (2008) Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. *BMC Cancer* 8: 72

ICNIRP (1998) Guidelines for limiting exposure to time-varying electric, magnetic and electromagnetic fields (up to 300 GHz). *Health Phys* 74: 494–522

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. *Cancer J Clin* 61(2): 69–90

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. *Cancer J Clin* 60(5): 277–300

Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. *Cancer J Clin* 54(1): 8–29

Kassianides C, Kew MC (1987) The clinical manifestations and natural history of hepatocellular carcinoma. *Gastroenterol Clin North Am* 16(4): 553–562

Kelly TL, Kripke DF, Hayduk R, Ryman D, Pasche B, Barbault A (1997) Bright light and LEET effects on circadian rhythms, sleep and cognitive performance. *Stress Med* 13: 251–258

Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. *Lancet* 362(9399): 1907–1917

Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, for the Panel of Experts in HCC-Design Clinical Trials (2008a) Design and endpoints of

Translational Therapeutics

clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst* **100**(10): 698–711

Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* **359**(9319): 1734–1739

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, the SHARP Investigators Study Group (2008b) Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* **359**(4): 378–390

Maruyama H, Yoshikawa M, Yokosuka O (2008) Current role of ultrasound for the management of hepatocellular carcinoma. *World J Gastroenterol* **14**(11): 1710–1719

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* **334**(11): 693–700

Pasche B, Erman MI, Hayduk R, Mitler M, Reite M, Higgs L, Dafni U, Amato D, Rossel C, Kuster N, Barbault A, Lebet JP (1996) Effects of low energy emission therapy in chronic psychophysiological insomnia. *Sleep* **19**: 327–336

Pasche B, Erman M, Mitler M (1990) Diagnosis and management of insomnia. *N Engl J Med* **323**: 486–487

Pasche B, Barbault A (2003) Low-energy emission therapy: current status and future directions. In *Bioelectromagnetic Medicine,* Rosch PJ, Markov MS (eds) pp 321–327. Marcel Dekker Inc.: New York, NY

Reite M, Higgs L, Lebet JP, Barbault A, Rossel C, Kuster N, Dafni U, Amato D, Pasche B (1994) Sleep inducing effect of low energy emission therapy. *Bioelectromagnetics* **15**: 67–75

Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson III AB, Salem R (2009) Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. *J Clin Oncol* **27**(34): 5734–5742

Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RSJ, Rafii S, Schwartz JD (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. *J Clin Oncol* **26**(18): 2992–2998

Simon R (1989) Optimal two-stage designs for phase II clinical trials. *Control Clin Trials* **10**(1): 1–10

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst* **92**(3): 205–216

Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. *J Clin Oncol* **23**(13): 2892–2899